Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Oct;97(4):1097-1102.
doi: 10.1213/01.ANE.0000080159.83342.B5.

Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy

Nathaniel P Katz  1 , Summer Sherburne, Michael Beach, Robert J Rose, Janet Vielguth, Joyce Bradley, Gilbert J Fanciullo
Affiliations

Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy

Nathaniel P Katz et al. Anesth Analg. 2003 Oct.

Abstract

No study has examined the role of urine toxicology in addition to behavioral monitoring in patients receiving opioid therapy for chronic pain. All patients maintained on chronic opioid therapy by the two senior authors at two university pain management centers were monitored for 3 yr with urine toxicology testing and for behaviors suggestive of inappropriate medication use. We retrospectively extracted demographic information, aberrant drug-taking behaviors, and urine toxicology information from the medical record. For 122 patients maintained on chronic opioid therapy, 43% (n = 53) had a "problem" (either positive urine toxicology or one or more aberrant drug-taking behaviors). Of patients with no behavioral issues, 21% (n = 26) had a positive urine screen for either an illicit drug or a nonprescribed controlled medication. Of patients with a negative urine screen, 14% (n = 17) had one or more behavioral issues. Monitoring both urine toxicology and behavioral issues captured more patients with inappropriate drug-taking behavior than either alone. Requiring a report of behavioral issues and urine toxicology screens for patients receiving chronic opioids creates a more comprehensive monitoring system than either alone.

Implications: Monitoring both urine toxicology and aberrant behavior in chronic-pain patients treated with opioids identified more problem patients than by monitoring either alone. The authors recommend routine urine testing on all patients prescribed opioids for noncancer pain and as a required element in all opioid analgesic studies.

PubMed Disclaimer

Comment in

References

    1. Turk D, Brody MC. What position do APS’s physician members take on chronic opioid therapy? Am Pain Soc Bull 1992; 2: 1–7.
    1. Bendsen P, Hensing G, Ebeling C, et al. What are the qualities of dilemma experienced when prescribing opioids in general practice? Pain 1999; 82: 89–96.
    1. Jamison RN, Raymond SA, Slawsby EA, et al. Opioid therapy for chronic noncancer back pain. Spine 1998; 23: 2591–600.
    1. Portenoy RK. Chronic opioid therapy in nonmalignant pain. J Pain Symptom Manage 1990; 5: S46–62.
    1. Dunbar SA, Katz NP. Chronic opioid therapy for nonmalignant pain in patients with a history of substance abuse: report of 20 cases. J Pain Symptom Manage 1996; 11: 163–71.

MeSH terms

Substances